ABSTRACT NUMBER: ESOC2026A1511 HYPERACUTE OUTCOMES OF INTRAVENOUS THROMBOLYSIS: RTPA VERSUS TENECTEPLASE (TNK)

Julieta Rosales, Matias Lopez, Manuel Chasco, Julieta Russo, Lylyk Pedro · 2026

Read ABSTRACT NUMBER: ESOC2026A1511 HYPERACUTE OUTCOMES OF INTRAVENOUS THROMBOLYSIS: RTPA VERSUS TENECTEPLASE (TNK) by Julieta Rosales, Matias Lopez, Manuel Chasco, Julieta Russo, Lylyk Pedro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145942.txt.

Description

Julieta Rosales and co-authors compare two clot-busting drugs for acute stroke in a 2026 conference abstract. Intravenous thrombolysis is a cornerstone of early stroke care, and tenecteplase has emerged as an alternative to the standard drug, alteplase. Real-world data on the fastest, hyperacute outcomes remain thin.

The team reviewed ninety-two patients treated within four and a half hours of symptom onset between January 2024 and December 2025. Just over half received tenecteplase and the rest alteplase, with similar starting profiles. Workflow times favored tenecteplase, with clearly shorter door-to-imaging, door-to-needle, and door-to-groin times. The abstract reports outcomes such as stroke scale scores at twenty-four hours and discharge, early improvement, and bleeding safety.

Catalog record

CREATORJulieta Rosales, Matias Lopez, Manuel Chasco, Julieta Russo, Lylyk Pedro
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13145942

Browse the full library · About the Tower of Babel